Malignancy Risks With Biologic Therapies

Rheumatic Disease Clinics of North America

Volumn 38, Issue 4, 2012, Pages 761-770

  Cush, John J ^a   Dao, Kathryn H ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

Biologic agent; Cancer; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL ACTIVITY; COLON CANCER; CROHN DISEASE; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; LUNG CANCER; MELANOMA; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN CANCER; SOLID TUMOR; T CELL LYMPHOMA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84868345439     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.09.006     Document Type: Review

References (33)

1. SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2012, National Cancer Institute, Bethesda (MD), Available at:, Accessed November 1, 2012. http://seer.cancer.gov/csr/1975_2009_pops09/, N. Howlader, A.M. Noone, M. Krapcho (Eds.).
2. Cush J.J., Dao K.H., Kay J. Does rheumatoid arthritis or biologic therapy increase cancer risk?. Drug Safety Quarterly 2012, 4(2):1-2. Available at:, Accessed November 1, 2012. http://www.rheumatology.org/publications/dsq/dsq_2012_08.pdf%23toolbar%3D1.
3. Lopez-Olivo M.A., Tayar J.H., Martinez-Lopez J.A., et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012, 308:898-908.
4. Smitten A.L., Simon T.A., Hochberg M.C., et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R45.
5. Hellgren K., Smedby K.E., Feltelius N., et al. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 2010, 62:1252-1258.
6. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701.
7. Cush JJ, Kavanaugh A. ACR Hotline: FDA Meeting March 2003: Update on the Safety of New Drugs for Rheumatoid Arthritis. American College of Rheumatology Web site. Available at: Accessed November 1, 2012. http://www.rheumatology.org/publications/hotline/0303TNFL.asp.
8. Mariette X., Matucci-Cerinic M., Pavelka K., et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011, 70:1895-1904.
9. Solomon D.H., Mercer E., Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 2012, 64:21-32.
10. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, (2). CD008794.
11. Parakkal D., Sifuentes H., Semer R., et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol 2011, 23:1150-1156.
12. Askling J., Fored C.M., Brandt L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426.
13. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895.
14. Simon T.A., Smitten A.L., Franklin J., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68:1819-1826.
15. Rennard S.I., Fogarty C., Kelsen S., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:926-934. COPD Investigators.
16. Silva F., Seo P., Schroeder D.R., et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011, 63:2495-2503. Wegener's Granulomatosis Etanercept Trial Research Group.
17. Wenzel S.E., Barnes P.J., Bleecker E.R., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558. T03 Asthma Investigators.
18. Burmester G.R., Panaccione R., Gordon K.B., et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, in press.
19. Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) FDA ALERT. 2009. Available at: Accessed November 11, 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm.
20. Cush J.J., Dao K. FDA Update: TNF inhibitors may increase risk of malignancy in children. Drug Safety Quarterly 2010, Available at:, Accessed November 1, 2012. http://www.rheumatology.org/publications/dsq/dsq_2010_01.pdf%23toolbar%3d1.
21. Kemper A.R., Van Mater H.A., Coeytaux R.R., et al. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr 2012, 12:29.
22. Bernatsky S., Rosenberg A.M., Oen K.G., et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 2011, 38:760-763.
23. Nordstrom B.L., Mines D., Gu Y., et al. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res 2012, 64:1357-1364.
24. Simard J.F., Neovius M., Hagelberg S., et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010, 62:3776-3782.
25. Beukelman T., Haynes K., Curtis J.R., et al. Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012, 64:1263-1271.
26. Watson K.D., Dixon W.G., Hyrich K.L., et al. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR Biologics Registry. Ann Rheum Dis 2006, 65(Suppl II):512.
27. Dixon W.G., Watson K.D., Lunt M., et al. British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010, 62:755-763.
28. Strangfeld A., Hierse F., Rau R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5..
29. Ji J., Liu X., Sundquist K., et al. Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology 2011, 50:1513-1518.
30. Franklin J., Lunt M., Bunn D., et al. Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 2007, 56:790-798.
31. Raaschou P., Simard J.F., Neovius M., et al. Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011, 63:1812-1822.
32. Carmona L., Descalzo M.A., Perez-Pampin E., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885. BIOBADASER and EMECAR Groups.
33. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.